bullish
Antengene Disconnect: Shares Down Despite Pipeline's Progress
305 Views21 Dec 2020 10:46
Shares remain below the IPO price despite XPOVIO's clinical progress. The weakness is an opportunity to buy shares in a top-quality, pre-revenue China biotech with a substantially de-risked lead drug.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- Antengene Disconnect: Shares Down Despite Pipeline's Progress21 Dec 2020
- Antengene: We Like the Deal10 Nov 2020
- Antengene (德琪医药) IPO: Buy the Team09 Nov 2020
- Antengene: Gunning To Move Up in Line06 Nov 2020
x